Back to Investors
Future Planet Capital

Future Planet Capital

Venture Capital

Future Planet Capital is a venture capital firm managing over $450m for public and private investors.

Portfolio

3

companies

AUM

£450M

under management


Portfolio companies

S

Spaceflux

Spaceflux provides advanced satellite tracking and space situational awareness solutions using artificial intelligence and optical sensors.

Nuclera

Nuclera

Nuclera provides benchtop systems that accelerate protein expression and purification for drug discovery.

Navenio

Navenio

Navenio provides indoor location technology and task allocation software to improve healthcare workflow efficiency.


Team

Douglas Hansen-Luke

Douglas Hansen-Luke

Executive Chairman

Douglas serves as Executive Chairman at Future Planet Capital, following roles including Chief Executive Officer at Robeco Middle East.

LinkedIn
Ed Phillips

Ed Phillips

Contact

Ed serves as a venture capitalist at Future Planet Capital and sits on the investment committee for the UK Innovation & Science Seed Fund. He also holds board and observer roles across several companies.

LinkedIn
AL

Alex Leigh

Investment Director Defence and Security


Recent investments

Seed
£5.4M

The seed round was co-led by Future Planet Capital, Foresight Group, and Blackfinch Ventures to accelerate growth in space situational awareness.

"As space becomes increasingly essential to our economy, environment and daily lives, it is also becoming more congested and contested. This investment strengthens our ability to protect satellite technology that delivers crucial insights to Earth around the clock, reducing collision risks, and supporting a safer, more sustainable space environment for future generations"
— Marco Rocchetto, CEO and co-founder
Series B
£31.4M

The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.

"There’s a fundamental productivity problem in biotech today. A biotech scientist needs to know how to make proteins to design drugs. That’s like expecting a computer scientist to know how to build a computer to design software,"
— Michael Chen, CEO
Series A
£9.5M

The Oxford Science Enterprises-led round will support US expansion and continued domestic growth in healthcare.

"I’m delighted our investors have again demonstrated their belief in the vast potential that Navenio can bring by ensuring ‘right person, right place, right time’. Artificial intelligence is one of many technologies making a real-world impact in the health sector, and this investment enables the company to rapidly spearhead international digital transformation."
— Niki Trigoni, Founder and CTO
Series A
£828K

Future Planet Capital backed the Oxford University spin-out to help hospitals manage infection risks and patient flows.

"Navenio exemplifies our investment thesis; best-in-class innovation from the world’s top university wrapped into a highly commercial product and company with the potential to scale its impact to help billions of lives. Having established partnerships with the NHS, Cleveland Clinic and some of the world’s largest outsourcers, we believe the company is poised to revolutionise healthcare efficiency worldwide. In addition, the core indoor geo-location engine developed at Oxford’s computer science lab, has achieved what competing tech giants in the space have not, and we believe this will be hugely valuable cross-industry."
— Douglas Hansen-Luke, Executive Chairman